Research article Open access
Evaluation of Ruxolitinib versus Best Available Therapy in Treating Primary Myelofibrosis
Objectives: This study aimed to evaluate the effectiveness of ruxolitinib and compare it with the best available therapy in patients with primary myelofibrosis. Ruxolitinib is a Janus kinase inhibitor that is approved for the treatment of myelofibrosis. The therapeutic protocol has changed after the introduction of rux …